Predict your next investment

Corporate Venture

See what CB Insights has to offer

Investments

2

Funds

1

About Colorcon Ventures

Colorcon Ventures is the venture arm of specialty ingredients firm Colorcon focused on investing in startups that are strategically relevant to the core Colorcon business.

Colorcon Ventures Headquarter Location

Harleysville, Pennsylvania, 19438,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Colorcon Ventures News

Colorcon Ventures Invests in i20 Therapeutics

Dec 7, 2020

Colorcon Ventures Invests in i20 Therapeutics Will work together to accelerate i2O’s research and development efforts. Contract Pharma Staff12.07.20 i2O Therapeutics , a biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from  Colorcon Ventures , the corporate venture fund of Colorcon Inc. In addition to this investment, Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts. i2O previously announced its seed round of financing led by Sanofi Ventures and JDRF T1D Fund in April 2020. “We welcome Colorcon Ventures as a strategic investor at this pivotal time of company growth,” said Ravi Srinivasan, Ph.D., chief executive officer of i2O Therapeutics. Founded by a team of researchers from Harvard University, i2O Therapeutics is focused on the development of safe and effective oral formulations of therapies that are conventionally limited to injections, e.g. biologics, large molecules, and peptide-based pharmaceuticals such as insulin. The company’s innovative platform enables drugs that traditionally would not survive the hostile environment of the digestive system to pass through safely by utilizing a unique coating that dissolves in the small intestine, thereby releasing the active drug. i2O’s initial focus is on developing a novel oral formulation for GLP-1 analogs. “We are excited to collaborate with Colorcon to help advance our ionic liquid technology given their rich history of innovation and expertise in pharmaceutical development,” said Samir Mitragotri, Ph.D., co-founder of i2O Therapeutics. “Colorcon Ventures’ strategic focus on technologies that transform conventional delivery pathways aligns well with i2O. The ability to deliver injectable therapies orally has the potential to significantly improve patient adherence and outcomes,” commented Martti Hedman, Colorcon’s chief executive officer. Dr. Ali Rajabi-Siahboomi, chief scientific officer of Colorcon stated, “Colorcon's excipients and in-depth pharmaceutical development expertise will help advance the use of ionic liquids for the oral delivery of challenging molecules.” Contract Pharma Staff 11.03.20 Contract Pharma Staff 10.29.20 Contract Pharma Staff 10.28.20 Contract Pharma Staff 10.12.20 Contract Pharma Staff 10.07.20 Contract Pharma Staff 09.25.20 Contract Pharma Staff 09.21.20 Contract Pharma Staff 08.31.20 Contract Pharma Staff 08.27.20 Contract Pharma Staff 08.26.20 Contract Pharma Staff 08.18.20 Contract Pharma Staff 08.17.20 Contract Pharma Staff 08.11.20 Contract Pharma Staff 08.04.20 Contract Pharma Staff 07.30.20

Colorcon Ventures Investments

2 Investments

Colorcon Ventures has made 2 investments. Their latest investment was in i2O Therapeutics as part of their Seed VC - II on December 12, 2020.

CBI Logo

Colorcon Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/3/2020

Seed VC - II

i2O Therapeutics

Yes

1

8/11/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/3/2020

8/11/2020

Round

Seed VC - II

Series B

Company

i2O Therapeutics

Subscribe to see more

Amount

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

10

Colorcon Ventures Fund History

1 Fund History

Colorcon Ventures has 1 fund, including Colorcon Ventures Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Colorcon Ventures Fund

$50M

1

Closing Date

Fund

Colorcon Ventures Fund

Fund Type

Status

Amount

$50M

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.